Total submissions: 8
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Mayo Clinic Laboratories, |
RCV001528592 | SCV005408915 | uncertain significance | not provided | 2024-03-21 | criteria provided, single submitter | clinical testing | |
| Gene |
RCV001528592 | SCV001814910 | likely benign | not provided | 2018-12-06 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV000461917 | SCV000543153 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2016-07-06 | criteria provided, single submitter | clinical testing | |
| Laboratory for Molecular Medicine, |
RCV000214672 | SCV000272743 | uncertain significance | not specified | 2015-04-14 | criteria provided, single submitter | clinical testing | The p.Asp2140Glu variant in TTN has not been previously reported in individuals with cardiomyopathy, but has been identified in 4/66660 European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org). Computa tional prediction tools and conservation analysis do not provide strong support for or against an impact to the protein. In summary, the clinical significance o f the p.Asp2140Glu variant is uncertain. |
| Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV001528592 | SCV001979320 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
| Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001528592 | SCV001967641 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
| Clinical Genetics, |
RCV001528592 | SCV001922029 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
| Diagnostic Laboratory, |
RCV001528592 | SCV001740565 | uncertain significance | not provided | no assertion criteria provided | clinical testing |